Holen Sie sich die Stockscreener-App
9.74
5.87%
0.54
Handel nachbörslich:
9.74
Schlusskurs vom Vortag:
$9.20
Offen:
$9.34
24-Stunden-Volumen:
786.54K
Relative Volume:
1.71
Marktkapitalisierung:
$1.31B
Einnahmen:
$53.99M
Nettoeinkommen (Verlust:
$-222.30M
KGV:
-5.3617
EPS:
-1.8166
Netto-Cashflow:
$-213.50M
1W Leistung:
+0.62%
1M Leistung:
-5.34%
6M Leistung:
+38.16%
1J Leistung:
+108.12%
1-Tages-Spanne:
$9.34
$10.00
1-Wochen-Bereich:
$9.13
$10.00
52-Wochen-Spanne:
$3.30
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
9.74 | 1.23B | 53.99M | -222.30M | -213.50M | -1.8166 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-05-28 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2020-11-20 | Eingeleitet | BofA Securities | Buy |
| 2020-09-22 | Eingeleitet | Goldman | Buy |
| 2020-07-27 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immatics N V Aktie (IMTX) Neueste Nachrichten
(IMTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Immatics N.V. (NASDAQ:IMTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immatics NV stock advances on promising TCR-T cell therapy data amid biotech rally - AD HOC NEWS
Immatics NV (IMTX) seeing strong enrollment in a key phase 3 trial of drug candidate - MSN
Fund Flows: Will Immatics NV Equity Warrant outperform its industry peers2026 Buyback Activity & Risk Controlled Swing Alerts - baoquankhu1.vn
IMTX SEC FilingsImmatics N.V 10-K, 10-Q, 8-K Forms - Stock Titan
Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX) - MSN
IMTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Immatics (IMTX) Expected to Announce Earnings on Thursday - MarketBeat
Immatics (IMTX) Chief Development Officer files Form 3 detailing equity - Stock Titan
Immatics (IMTX) CMO Cedrik Britten reports option, RSU and share holdings - Stock Titan
Immatics General Counsel reports option and RSU holdings | IMTX SEC FilingForm 3 - Stock Titan
[Form 3] Immatics N.V. Initial Statemen... - Stock Titan
Immatics (IMTX) CEO reports options, RSUs and share holdings - Stock Titan
Immatics (IMTX) director reports sizeable stock option holdings - Stock Titan
Immatics (IMTX) CFO reports 350,000 stock options holding - Stock Titan
Immatics N.V. (IMTX) director Eliot Forster details stock option holdings - Stock Titan
Immatics (IMTX) Chief People Officer reports 211,000 share options on Form 3 - Stock Titan
Immatics (IMTX) director discloses existing stock option grants - Stock Titan
Immatics (IMTX) director discloses multiple long-dated stock options - Stock Titan
Immatics (IMTX) director reports multiple long-dated stock option grants - Stock Titan
Immatics (IMTX) COO details stock options, RSUs and share holdings - Stock Titan
Immatics (IMTX) CBO details stock option and RSU positions - Stock Titan
Immatics (IMTX) director Chambre details ordinary share and option stakes - Stock Titan
Immatics (IMTX) director Michael G. Atieh reports stock option positions - Stock Titan
Immatics (IMTX) Chief Innovation Officer discloses option and RSU stakes - Stock Titan
Why Immatics (IMTX) Is Down 6.4% After Deepening Losses And Highlighting SUPRAME Phase 3 Progress - simplywall.st
Immatics (IMTX) director entities disclose indirect share and option stakes - Stock Titan
Aug PreEarnings: What is the target price for Immatics NV stockWeekly Trading Summary & Verified Technical Signals - baoquankhu1.vn
Risk Check: Is Immatics NV a defensive stock2026 Winners & Losers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Immatics NV Stock (ISIN: NL0015255052) Advances on Promising TCR-T Therapy Data Amid Biotech Sector - AD HOC NEWS
Immatics N.V. (IMTX) director Hothum discloses options and indirect shares - Stock Titan
IMTX: Jefferies Analyst Biren Amin Rates Immatics with a "Buy" and Sets Price Target at $18.00 | IMTX Stock News - GuruFocus
Immatics (NASDAQ:IMTX) Stock Price Up 9.3%Here's What Happened - MarketBeat
Immatics (NASDAQ:IMTX) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside - Yahoo Finance
Immatics N.V. $IMTX Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Immatics NV Stock (ISIN: NL0015255052) Holds Steady Amid Biotech Sector Volatility - AD HOC NEWS
(IMTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate - Insider Monkey
Can Immatics NV Equity Warrant generate free cash flow2026 Market Sentiment & Target Return Focused Stock Picks - baoquankhu1.vn
Immatics (NASDAQ:IMTX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Immatics (NASDAQ:IMTX) Shares Gap DownTime to Sell? - MarketBeat
Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)? - simplywall.st
Jefferies Financial Group Inc. Takes $10.18 Million Position in Immatics N.V. $IMTX - MarketBeat
Insider Buy: What is the target price for Immatics NV stockDay Trade & Real-Time Volume Triggers - baoquankhu1.vn
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to "Hold" - MarketBeat
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to “Hold” - Defense World
Is Immatics N.V. Equity Warrant stock near bottom after declineGold Moves & Low Risk Growth Stock Ideas - Naître et grandir
Finanzdaten der Immatics N V-Aktie (IMTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):